Cancer Genomics: the future of personalized medicine
2012 Bioscience Leader of the Year, Robert Penny, MD, PhD shares the history of the Cancer Genome Atlas Project and a look forward at the future of personalized medicine.
Tying it all together for start up success
Alan Nelson is heading the Predictive Health Analytics Initiative that aims to change the paradigm in healthcare from treating late stage disease to early diagnosis and preventive therapies that are cost-effective. He served as the Executive Director of the Biodesign Institute at ASU and holds professorships in Bioengineering and physics. He is the founder and CEO of three companies, the most recent being VisionGate, the innovator of the LuCED lung cancer early detection test. VisionGate was awarded the start-up of the year award at the recent Governors’ celebration of innovation. Alan has a PhD in Biophysics from Berkeley, holds 66 issued patents, and has published over 100 scholarly papers in biomedical imaging.
Keeping People Healthy...at a cost we can afford (Full Presentation)
Michael Birt, director of the Center for Sustainable Health at the Biodesign Institute at Arizona State University. In Birt’s address, “Sustaining Health: How Do We Prevent and Detect Disease Early Enough to Keep People Healthy … at a Cost We Can Afford?” he calls for a shift in our health system to reward cost-effective prevention, early detection and intervention. Such a shift and the technology that it would require has the potential to spur growth among bioscience organizations, reduce patient suffering, and lowering health care costs.
Company Presentation: NuvOx
NuvOx Pharma is a biotechnology company based in Tucson, Arizona with a novel patent portfolio allowing it to develop an innovative platform of dodecafluoropentane (DDFP)-based oxygen therapeutics to treat a host of human conditions. Founded in 2008, NuvOx Pharma has demonstrated therapeutic feasibility in radiation-resistant cancer, hemorrhagic shock, traumatic brain injury, myocardial infarction, retinopathy and stroke. Due to inherent structure of DDFP, a very stable and relative lack of inter-molecular attractive forces, this perfluorocarbon is known to carry large payloads of oxygen in the bloodstream. The main advantage to using DDFP is that it is a liquid at room temperature, but expands to the gas state in the body. Therefore, upon intravenous injection the transition of DDFP from a liquid to a gas in the bloodstream allows for ~600 times increased oxygen transport compared to Hemoglobin.
From Bioscience to Biobusiness Success
Dr. Robert Bowser was recruited to the Barrow Neurological Institute and St. Joseph’s Hospital & Medical Center to direct an ALS research center using philanthropic support from Mr. Ira Fulton. He arrived to the Phoenix area in August of last year after 18 years on the faculty at the University of Pittsburgh School of Medicine. Dr. Bowser’s research focuses on biomarkers of neurologic disease and he will describe how success in his academic research has also led to success in the world of biotechnology.
Senestech: Humane Pest Control
Senestech is a platform biotechnology company specializing in reproductive physiology. Our mission: Senestech aims to provide for the more humane treatment of animals, to improve the quality of human life, and to enhance environmental stewardship through global application of our animal fertility control technology. We are currently applying our revolutionary technology to the control of rats and mice in both agricultural and urban settings.
Watson and the Future of Healthcare (Full Presentation)
IBM’s Watson and future strategies for advancing health. David Kerr, Director, Corporate Strategy, IBM, Armonk, N.Y.
Company Presentation: Invoy Technologies, LLC
Exhaled Breath: A Portal for Pain-Free Biochemical Analysis Invoy is engaged in the development and commercialization of breath analysis devices for a broad range of applications. Invoy plans to offer patients the ability to monitor their health in the convenience of their own home – with a prescription-based breath analysis device called the Voyager. The process is pain-free and the results are quick and accurate; giving patients peace of mind and confidence in using this new-to-the-market device.